Wells Fargo
QNCX icon

Wells Fargo’s Quince Therapeutics QNCX Stock Holding History

Wells Fargo’s Portfolio QNCX Stock Details QNCX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-35
Closed -$23.4K – 7403
2025
Q4 		$23.4K Hold
35
– – ﹤0.01% 5755
2025
Q3 		$11.4K Hold
35
– – ﹤0.01% 5919
2025
Q2 		$11.5K Buy
+35
New +$8K ﹤0.01% 5916
2024
Q2 		– Sell
-1
Closed -$284 – 7351
2024
Q1 		$284 Sell
1
-5
-83% -$1.24K ﹤0.01% 6415
2023
Q4 		$1.33K Hold
6
– – ﹤0.01% 6164
2023
Q3 		$1.36K Buy
6
+5
+500% +$1.31K ﹤0.01% 6154
2023
Q2 		$232 Hold
1
– – ﹤0.01% 6658
2023
Q1 		$229 Hold
1
– – ﹤0.01% 6739
2022
Q4 		$92 Sell
1
-5
-83% -$836 ﹤0.01% 6814
2022
Q3 		$2K Sell
6
-1
-14% -$381 ﹤0.01% 6185
2022
Q2 		$3K Sell
7
-86
-92% -$60.8K ﹤0.01% 6211
2022
Q1 		$114K Sell
93
-89
-49% -$121K ﹤0.01% 5259
2021
Q4 		$459K Buy
182
+133
+271% +$812K ﹤0.01% 4728
2021
Q3 		$907K Sell
49
-13
-21% -$207K ﹤0.01% 4308
2021
Q2 		$657K Buy
62
+3
+5% +$25.2K ﹤0.01% 4478
2021
Q1 		$425K Sell
59
-99
-63% -$712K ﹤0.01% 4774
2020
Q4 		$878K Buy
158
+80
+103% +$709K ﹤0.01% 4124
2020
Q3 		$776K Sell
78
-15
-16% -$136K ﹤0.01% 4047
2020
Q2 		$859K Buy
93
+14
+18% +$128K ﹤0.01% 3927
2020
Q1 		$724K Buy
79
+11
+16% +$109K ﹤0.01% 3758
2019
Q4 		$766K Buy
68
+27
+66% +$163K ﹤0.01% 4042
2019
Q3 		$203K Buy
41
+19
+86% +$117K ﹤0.01% 4955
2019
Q2 		$191K Buy
+22
New +$131K ﹤0.01% 5003

Other funds holding QNCX

WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
SC
Shay Capital New York $1.2B AUM 37.47% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
IC
IEQ Capital Foster City, California $21.5B AUM 75.26% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Wells Fargo's QNCX Position: Q1 2026 in Review

Wells Fargo sold out of Quince Therapeutics (QNCX) in Q1 2026, closing a stake of 35 shares — an estimated $23.4K sold.

Wells Fargo first reported a position in QNCX in Q2 2019 and held it in 23 quarters. The position peaked at $907K in Q3 2021. 43 funds tracked by Wall St. Rank hold QNCX as of Q1 2026.

  • Wells Fargo reported no remaining Quince Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Wells Fargo sold 35 Quince Therapeutics shares in Q1 2026, an estimated $23.4K.
  • Wells Fargo first reported a position in Quince Therapeutics in Q2 2019 and held it in 23 quarters.
  • Wells Fargo's Quince Therapeutics position peaked at $907K in Q3 2021.
  • 43 funds tracked by Wall St. Rank held Quince Therapeutics as of Q1 2026.

Based on Wells Fargo's 13F filing for Q1 2026, filed 11 May 2026.